About the Company
We do not have any company description for Quince Therapeutics, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Quince Therapeutics, Inc.
Quince Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s ...
Quince Therapeutics Appoints Former Reata ... - Business Wire
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology that leverages a patien ...
Quince, Niagen, Intrabio busy in rare A-T disease
Quince Therapeutics Inc.’s mid-July completion of enrollment in the pivotal phase III study in ataxia-telangiectasia (A-T) marked an important milestone for the South San Francisco-based firm, which ...
Quince Therapeutics Completes the Sale of Legacy Protease ... - Nasdaq
Quince Therapeutics, Inc., a biopharmaceutical company advancing innovative precision therapeutics targeting debilitating and rare diseases, announced the sale of the company’ s legacy small ...
Quince Therapeutics Receives Notice of Allowance Covering Innovative ...
Quince Therapeutics, Inc. (Nasdaq: QNCX) is a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases.
Quince Therapeutics to Participate at A-T Society’s 2025 A-T Clinical ...
Quince Therapeutics, Inc. (Nasdaq: QNCX) is a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases.
Quince Therapeutics Provides Business Update and Reports First Quarter ...
About Quince Therapeutics Quince Therapeutics, Inc. is a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases.
Quince Therapeutics Selects Option Care Health as Specialty Infusion Therapy Provider for Administration of Lead Asset eDSP
SOUTH SAN FRANCISCO, Calif. & BANNOCKBURN, Ill., August 07, 2025--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage ...
Geode Capital Management LLC Has $703,000 Stock Position in Quince ...
Geode Capital Management LLC raised its holdings in Quince Therapeutics, Inc. (NASDAQ:QNCX – Free Report) by 10.9% during the 4th quarter, according to the company in its most recent disclosure ...
Cortexyme Corporate Name Change to Quince Therapeutics to Take ... - Nasdaq
Cortexyme, Inc. today announced that the company’ s planned corporate name change to Quince Therapeutics is expected take effect on Monday, August 1, 2022. Additionally, the company’ s ticker ...
Quince Therapeutics Provides Business Update and Reports Third Quarter ...
About Quince Therapeutics Quince Therapeutics, Inc. is a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases.
Similar Companies
Loading the latest forecasts...